Research Rankings
Peptide Weight Loss Research Rankings: The Leaderboard Through 2024
Hundreds of peptide compounds appear in fat-loss and metabolic research. These are the ones with the most citations, the broadest mechanistic coverage, and the strongest evidence tiers.
How We Scored the Leaderboard
Every compound here was evaluated on four criteria: total indexed study count on PubMed, highest evidence tier reached (human RCT scores highest, then small human study, then animal, then in-vitro only), mechanism diversity (how many distinct biological pathways are documented), and recency of active research. Each criterion was weighted equally, producing a composite score that determines rank order.
One critical distinction runs through every entry: FDA approval belongs to specific branded drugs, not to the peptide molecule itself. Where an approved pharmaceutical exists, that approval is noted and attributed to the brand. Research-chemical versions of those same molecules are not approved by the FDA and are not equivalent to the prescription product. That line is drawn clearly at every rank.
Evidence tier labeling is non-negotiable here. A compound backed only by rodent studies does not get the same credibility score as one with phase 3 RCT data in thousands of humans. Readers comparing these compounds need that context upfront, not buried in footnotes.
Rank 1 and 2: The GLP-1 Class Dominates the Standings
Semaglutide holds the top position by a wide margin. As of 2024, PubMed lists over 3,000 indexed publications involving semaglutide and weight or obesity outcomes. The STEP 1 trial (2021, New England Journal of Medicine, n=1,961) reported a mean body weight reduction of 14.9% over 68 weeks in adults with obesity who received the branded drug Wegovy. That trial is an RCT, the highest evidence tier. Wegovy (semaglutide injection 2.4 mg) is FDA-approved for chronic weight management. Research-chemical semaglutide sold outside that pharmaceutical supply chain is not approved.
Tirzepatide ranks second. It targets both the GIP and GLP-1 receptors, giving it a dual-agonist mechanism that semaglutide does not share. The SURMOUNT-1 trial (2022, New England Journal of Medicine, n=2,539) showed mean weight reductions of up to 20.9% at the highest dose studied over 72 weeks. Zepbound (tirzepatide) received FDA approval for chronic weight management in November 2023. Mounjaro (tirzepatide) holds a separate approval for type 2 diabetes. Research-chemical tirzepatide is not approved. The dual-mechanism angle gives tirzepatide the highest mechanism-diversity score of any compound on this list.
Both compounds score maximum points on evidence tier and study volume. Their separation from the rest of the leaderboard is substantial. The next-ranked compound has fewer than 10% of the indexed human studies that semaglutide carries.
Rank 3: Tesamorelin and the GHRH Pathway
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It occupies a different mechanistic lane than GLP-1 agonists, stimulating pituitary release of growth hormone rather than acting on gut-derived satiety signals. That mechanism diversity earns it a strong score in that category. The FDA approved Egrifta (tesamorelin) specifically for HIV-associated lipodystrophy, a condition involving excess visceral fat in people on antiretroviral therapy. That approval is narrow and condition-specific. Use of tesamorelin outside that indication, including general weight loss, is not FDA-approved.
A 2010 phase 3 RCT published in the New England Journal of Medicine (n=412) found that participants receiving tesamorelin showed a 15.2% reduction in visceral adipose tissue versus 5.0% in the placebo group over 26 weeks. That RCT data is what pushes tesamorelin to rank 3 over compounds with only animal data. Study volume is lower than the GLP-1 class, but the evidence tier is legitimate.
Researchers have also examined tesamorelin's effects on IGF-1 levels and cognitive outcomes in non-HIV populations, which adds to its mechanism-diversity score. Those studies are smaller and do not constitute approval for those uses.
Ranks 4 and 5: AOD-9604 and CJC-1295 in the Growth Hormone Fragment Category
AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal region (amino acids 176-191). It received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient in 2014, but it is not approved as a drug for weight loss. Early human studies, including a phase 2b trial published in Obesity Research (2004, n=300), examined its effects on body weight over 12 weeks. Results were mixed and did not support further phase 3 development for obesity at the time. That trial history is why AOD-9604 ranks 4th rather than higher: it has human data, but the data did not produce a clear positive signal strong enough to advance.
CJC-1295 is a GHRH analog with a longer half-life than native GHRH due to drug affinity complex (DAC) technology. Most of its published research involves growth hormone pulse amplitude and IGF-1 elevation in small human studies. A 2006 study in the Journal of Clinical Endocrinology and Metabolism (n=65) documented sustained GH elevation. Direct fat-loss outcomes in humans are not well-documented in RCTs. CJC-1295 scores lower on evidence tier than AOD-9604 because its weight-related data is largely indirect and preclinical. It ranks 5th primarily on mechanism-diversity points and study recency.
Both compounds are research chemicals. Neither holds FDA approval for weight management or any other indication in their research-chemical forms.
Honorable Mentions: BPC-157, Ipamorelin, and the Preclinical Tier
BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. Its weight-related research is almost entirely in rodent models. A 2019 study in Current Pharmaceutical Design examined its effects on metabolic parameters in rats. There are no published human RCTs on BPC-157 for weight loss as of 2024. It scores high on mechanism diversity because researchers have studied it across gastrointestinal, musculoskeletal, and neurological pathways, but its evidence tier for fat loss specifically is preclinical only. Readers should weight that accordingly.
Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. Like CJC-1295, its documented effects on body composition in humans are limited. Most published data comes from animal studies or small human trials focused on GH pulse frequency rather than fat mass directly. A 1998 study in the European Journal of Endocrinology characterized its GH-releasing properties in humans (n=8), but that sample size is too small to draw weight-loss conclusions. Ipamorelin's rank stays in the honorable-mention tier because of that evidence gap.
Peptide YY (PYY) and oxyntomodulin are gut-derived peptides that have appeared in appetite-suppression research, including small human studies. PYY(3-36) was studied in a 2002 Nature paper (n=12) showing reduced caloric intake after infusion. These compounds have not advanced to large RCTs for weight management and remain in early research phases. They are included here to give readers a complete picture of the research field rather than a false impression that only the top-ranked compounds exist.
Frequently asked questions
What is the difference between a peptide studied for weight loss and an FDA-approved weight-loss drug?
FDA approval requires a compound to complete phase 1, 2, and 3 clinical trials demonstrating safety and efficacy for a specific indication in a specific population, then pass FDA review. Most peptides on this list have not completed that process for weight loss. Semaglutide as Wegovy and tirzepatide as Zepbound have completed it. Research-chemical versions of those molecules, or any peptide sold outside the approved pharmaceutical supply chain, do not carry that approval regardless of how similar their molecular structure is to the approved drug.
Why does evidence tier matter when comparing peptides in weight loss research?
A rodent study showing fat reduction does not predict the same outcome in humans. Rodent metabolism, hormonal signaling, and gut microbiome differ substantially from human physiology. Small human studies (under 30 participants) can establish biological plausibility but are underpowered to detect meaningful effect sizes or rare adverse events. Only large, randomized, placebo-controlled trials in humans provide the kind of evidence that supports confident conclusions about weight outcomes. Compounds like semaglutide and tirzepatide have that data. Most others on this list do not, and that gap is the most important number on the leaderboard.
Are any of the lower-ranked peptides likely to move up the leaderboard in coming years?
ClinicalTrials.gov lists ongoing studies for several compounds in this tier. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has phase 2 data published in the New England Journal of Medicine (2023, n=338) showing up to 24.2% body weight reduction over 48 weeks, which would place it near the top of this leaderboard if phase 3 results replicate those findings. Compounds with active phase 2 or 3 trials are the most likely candidates to move up. Compounds with only animal data and no registered human trials are unlikely to change rank in the near term.
Sources
- Wilding et al., 2021, New England Journal of Medicine (STEP 1 trial, semaglutide) · Phase 3 RCT, semaglutide 2.4 mg, weight outcomes
- Jastrzebski et al., 2022, New England Journal of Medicine (SURMOUNT-1, tirzepatide) · Phase 3 RCT, tirzepatide, weight outcomes
- Falutz et al., 2010, New England Journal of Medicine (tesamorelin, HIV lipodystrophy) · Phase 3 RCT, tesamorelin, visceral fat reduction
- Heffernan et al., 2006, Journal of Clinical Endocrinology and Metabolism (CJC-1295) · Small human study, GH and IGF-1 elevation
- Batterham et al., 2002, Nature (PYY3-36, appetite suppression) · Small human study, PYY infusion and caloric intake
This ranking report is educational and informational content only and is not medical advice. The compounds discussed are research chemicals that are not approved for human use outside prescribed clinical contexts. Rankings reflect vendor documentation quality, not product safety or efficacy. Consult a licensed healthcare provider before considering any compound.